Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial

IMPORTANCE: We assessed feasibility of monthly subcutaneous administration of PF-06801591, a humanized immunoglobulin G4 monoclonal antibody that binds to the programmed cell death (PD-1) receptor and blocks its interaction with PD-1 ligands. OBJECTIVE: To evaluate the safety, efficacy, and pharmaco...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Johnson, Melissa L., Braiteh, Fadi, Grilley-Olson, Juneko E., Chou, Jeffrey, Davda, Jasmine, Forgie, Alison, Li, Ruifeng, Jacobs, Ira, Kazazi, Farhad, Hu-Lieskovan, Siwen
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2019
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6547134/
https://ncbi.nlm.nih.gov/pubmed/31145415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0836
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi